Table 7.

Characteristics of DrotAA-treated pediatric patients with PF, MEN, or MD and experienced a serious bleeding event

Characteristic	During infusion			After infusion
Day of event1	1	1	7	8	10	UD	UD
Bleeding event
ICH	No	No	No	Yes	No	Yes	Yes
Fatal	No	No	No	Yes	No	Yes	No
DrotAA related2	No	No	No	Yes	No	No	No
Disease category
PF	Yes	Yes	Yes	Yes	Yes	No	Yes
MEN	No	Yes	No	No	No	Yes	No
MD	Yes	Yes	Yes	Yes	Yes	Yes	No
Baseline characteristics
Protein C level (%)	36	-	16	41	-	34	-
Platelet count	26	23	33	30	68	71	14
APTT (s)	68	165	121	220	73	111	-
PT (s)	23	38	22	-	-	17	16
Organ failure	3	4	3	4	1	-	-

¹Day 0 is defined as the calendar day on which DrotAA treatment began; ²This denotes whether or not the investigator considered the bleeding event to be related to treatment with DrotAA. APTT, activated partial thromboplastin time; BL, baseline; DrotAA, drotrecogin alfa (activated); ICH, intracranial hemorrhage; PT, prothrombin time; UD, unknown day after infusion. A dash indicates missing data.